Patents by Inventor Elizabeth Anne Skidmore

Elizabeth Anne Skidmore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxadiazole derivatives as Rho-Kinase Inhibitors
    Patent number: 11578068
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are oxidazole derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: February 14, 2023
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Christine Edwards, Elizabeth Anne Skidmore
  • OXADIAZOLE DERIVATIVES AS RHO-KINASE INHIBITORS
    Publication number: 20200331912
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are oxidazole derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 12, 2018
    Publication date: October 22, 2020
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Christine EDWARDS, Elizabeth Anne SKIDMORE
  • QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS
    Publication number: 20130030001
    Abstract: The invention provides named compounds of formula (I), pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions and their use in therapy.
    Type: Application
    Filed: August 1, 2012
    Publication date: January 31, 2013
    Applicants: PULMAGEN THERAPEUTICS (SYNERGY) LIMITED, ASTRAZENECA AB
    Inventors: Richard James BULL, Elizabeth Anne SKIDMORE, Rhonan Lee FORD, Andrew Nigel MATHER, Antonio METE
  • QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS
    Publication number: 20110172237
    Abstract: The invention provides named compounds of formula (I), wherein R4 is a N-substituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for’ the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.
    Type: Application
    Filed: May 13, 2008
    Publication date: July 14, 2011
    Inventors: Richard James Bull, Elizabeth Anne Skidmore, Rhonan Lee Ford, Andrew Nigel Mather, Antonio Mete